China Pharma Holdings (CPHI) Net Cash Flow (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Net Cash Flow came in at -$134617.0 in Q1 2026, up 35.53% YoY from -$99323.1 in Q1 2025, and down 282.83% on a QoQ basis from $73631.0 in Q4 2025.
China Pharma Holdings (CPHI) Net Cash Flow (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Net Cash Flow data on file, last reported at -$134617.0 in Q1 2026.
- Quarterly Net Cash Flow rose 35.53% year-over-year to -$134617.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$208814.0 (up 37.48% YoY) and the FY2025 annual result came in at -$283017.0, up 61.31% from the prior year.
- Net Cash Flow eased to -$134617.0 in Q1 2026, from $73631.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $463427.0 in Q3 2023 to a low of -$1.4 million in Q2 2022.
- A 5-year average of -$255334.4 and a median of -$65874.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 9298.63% — and 2025, when it sank 1194.31%.
- Tracing CPHI's Net Cash Flow over 5 years: stood at -$60201.0 in 2022, then surged by 105.86% to $3528.0 in 2023, then slumped by 905.33% to -$28412.0 in 2024, then surged by 359.15% to $73631.0 in 2025, then slumped by 282.83% to -$134617.0 in 2026.
- The last three Net Cash Flow figures came in at -$134617.0 (Q1 2026), $73631.0 (Q4 2025), and -$399799.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | China Pharma Holdings | 42.55 Mn | 42.24 Mn | 83,566.00 | 87,290.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134,617.00 |
| Mar 31, 2026 | -134,617.00 |
| Dec 31, 2025 | 73,631.00 |
| Dec 31, 2025 | 73,631.00 |
| Sep 30, 2025 | -399,799.00 |
| Sep 30, 2025 | -399,799.00 |
| Jun 30, 2025 | 251,971.00 |
| Jun 30, 2025 | 251,971.00 |
| Mar 31, 2025 | -208,820.00 |
| Mar 31, 2025 | -208,820.00 |
| Dec 31, 2024 | -28,412.00 |
| Dec 31, 2024 | -28,412.00 |
| Sep 30, 2024 | -30,889.00 |
| Sep 30, 2024 | -30,889.00 |
| Jun 30, 2024 | -65,874.00 |
| Jun 30, 2024 | -65,874.00 |
| Mar 31, 2024 | -578,302.00 |
| Mar 31, 2024 | -578,302.00 |
| Dec 31, 2023 | 3,528.00 |
| Dec 31, 2023 | 3,528.00 |